-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Cronos Stock Watchers Should Wait For Further Declines Before Buying
Add in the Altria connection, and Cronos stock could be a big winner. But that's over a long time horizon. Until then, the best play is to wait for shares to reach a more reasonable valuation.
Aphria Needs Strong Sales Growth to Rise High Again
What does the future look like for Aphria stock? It depends on its success in growing market share and international sales.
Gilead Sciences Stock: Still Cheap but Don’t Count On a Coronavirus Rally
Gilead Sciences has scored a lot of attention with its drug that may treat coronavirus. That doesn't necessarily make GILD stock a buy yet, though.
Healthcare Robotics and the Timely Lesson of My First Big Investing Mistake
Intuitive Surgical is one of Matt McCall's most important stock purchases. He's had much bigger gainers … but it taught him a very important lesson.
Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15%
Pfizer stock is gearing up for a strong 2020 as the company spins out is generics drug business, completing a merger with Mylan.
Can Aurora Cannabis Climb Its Massive Wall of Worry?
Aurora stock has a massive wall of worry it has to climb, and I expect more than a few missteps that eventually lead to total collapse.
Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
Don’t Lump OrganiGram Stock With All the Other Downtrodden Pot Stocks
Even during a challenging time for the broader canna-business, there are still a few good reasons to hold onto OrganiGram stock.
Cronos Stock Just Raised a Massive Red Flag
Cronos has delayed its quarterly and annual earnings report by at least two weeks while it conducts an audit of its financials. Until that audit is complete, the stock will likely underperform.
Patience Will Be Rewarded for Investors in Beaten-Up Cronos Stock
It may take awhile for it to materialize, but beaten-up Cronos stock could eventually turn into a multi-bagger for investors.
Approaching $1, Aurora Cannabis Stock Is Not for the Faint of Heart
Aurora stock is continuing its downtrend and bullish momentum left the cannabis space. Investors must proceed with caution.
Constellation Brands’ Sad Fate Seems Written in the Stars
Constellation Brands and STZ stock once earned a premium for its CGC investment. Now it seems guaranteed to head lower.
The Bull Case for New Age Beverages Stock Still Isn’t Strong Enough
Although New Age Beverages has an exciting product pipeline, it still isn't a good enough reason to to own NBEV stock right now.
Aurora Cannabis Is Approaching Baseball’s Mendoza Line
Aurora stock could hit the stock market's version of the Mendoza Line, the $1 mark, if companies can't take market share from street dealers.
It’s High Time Investors Buy Some Canopy Growth Shares
After Canopy's solid earnings report, charts are indicating that it has hit a bottom. It's time for investors to pick up some CGC stock now.
Canopy Growth’s Future Is Still Very Bright
Canopy Growth reported strong sales numbers and updated investors on its U.S. expansion. CGC stock still looks bright.
Even Under $2, Aurora Stock Remains Unattractive
Accelerated cash burn is a concern for Aurora stock, coupled with sluggish growth in medicinal and recreational cannabis. Further ACB equity dilution coming.
